دورية أكاديمية

Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay

التفاصيل البيبلوغرافية
العنوان: Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay
المؤلفون: Massart, Catherine1 catherine.massart@chu-rennes.fr, Gibassier, Jacqueline1, de Seze, Jérôme2, Debouverie, Marc3, Moreau, Thibault4, Pelletier, Jean5, Vermersch, Patrick6, Edan, Gilles7
المصدر: Clinica Chimica Acta. May2008, Vol. 391 Issue 1/2, p98-101. 4p.
مصطلحات موضوعية: *IMMUNOGLOBULINS, *VESICULAR stomatitis, *VIRUS diseases, *FIRE assay
مستخلص: Abstract: Introduction: Neutralizing antibodies (NAb) against interferon beta (IFNβ) reduce treatment efficacy in patients with multiple sclerosis (MS). Objective: We used the cross-reactivity of NAbs against IFNβ-1a or IFNβ-1b for improving the sensitivity of NAb measurement. Patients/methods: The study included sera from 185 MS patients treated at least 12 months (T1) with IFNβ-1a (Rebif®; n =62 or Avonex®; n =61) or IFNβ-1b (Betaferon®; n =62). NAbs were measured by CPE in all the sera using the WISH cell line infected by the bovine stomatitis vesicular virus. NAb titres were expressed in ten-fold reduction (TRU)/mL. NAb-positive titres at T1 were also measured 3 to 6 months later (T2). Results: At T1, with the classical CPE assay using the IFNβ type (1a or 1b) according to the molecule administered, 29/180 (15.7%) patients had positive NAb titres: 9/62 (14.5%), 14/62 (22.6%) and 6/61 (9.8%) subjects were treated with Betaferon®, Rebif® and Avonex®, respectively. When IFNβ-1a (Rebif® or Avonex®) was used, NAb-positive results were found in 33/185 (17.8%) patients. They included the 29 patients previously found positive with the classical CPE method and 7 other subjects treated with Betaferon® and NAb-negative against IFNβ-1b. All the 33 NAb-positive patients at T1 were positive 3 to 6 months later. Conclusion: IFNβ-1a should be used for the NAb determination for an optimal evaluation of NAb-positive patients in MS patients treated with IFNβ. [Copyright &y& Elsevier]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:00098981
DOI:10.1016/j.cca.2008.01.016